• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Algernon Pharmaceuticals Inc (OP: AGNPF )

    0.0461 -0.0142 (-23.55%)
    Streaming Delayed Price Updated: 9:30 AM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 640
    Open 0.0603
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0603
    Today's Range 0.0461 - 0.0643
    52wk Range 0.0353 - 0.1230
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design
    Via Benzinga

    Performance

    YTD
    -28.08%
    -28.08%
    1 Month
    -29.94%
    -29.94%
    3 Month
    -45.64%
    -45.64%
    6 Month
    -48.03%
    -48.03%
    1 Year
    -14.79%
    -14.79%

    More News

    Read More
    Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
    Via Benzinga
    DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study
    Via Benzinga
    Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study
    Via Benzinga
    DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
    Via Benzinga
    How To Finance A Psychedelics Business? Learn From These Four Companies
    Via Benzinga
    Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment
    Via Benzinga
    Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
    Via Benzinga
    Algernon Pharmaceuticals AP-188 DMT Compound Shows Promise For The Treatment Of TBI
    Via Benzinga
    Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program
    Via Benzinga
    Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
    Via Benzinga
    Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
    Via Benzinga
    Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program
    Via Benzinga
    Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose
    Via Benzinga
    A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
    Via Benzinga
    Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
    Via Benzinga
    EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
    Via Benzinga
    Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
    Via Benzinga
    Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
    Via Benzinga
    Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video
    Via Newsfile
    Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University
    Via Benzinga
    A Foundational Study On Stroke Is Ready. Here Is Why It's Important
    Via Benzinga
    Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment
    Via Benzinga
    Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.